GlassScriptPhysician profile
George W Poche
NPI 1275521932
$8,979.59
in general payments reported to CMS, 2019-2025
20 companies · $2,493 in 2025
The $2,493 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $546 · 2021: $574 · 2022: $1,030 · 2023: $1,271 · 2024: $1,776 · 2025: $2,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,340 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,340.17 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,403.55 | 2019-2025 | |
| Lilly USA, LLC | $1,393.92 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $945.05 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $804.75 | 2019-2025 | Tremfya |
| Genzyme Corporation | $676.24 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $643.57 | 2019-2025 | |
| Leo Pharma INC. | $422.01 | 2022-2025 | Adbry |
| Ucb, INC. | $345.64 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Scientific Affairs, LLC | $225.22 | 2024-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $204.95 | 2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $170.84 | 2019-2025 | Libtayo, Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.77 | 2025 | Spevigo |
| Incyte Corporation | $121.28 | 2022-2024 | Opzelura |
| Amgen INC. | $107.52 | 2019-2022 | |
| Dermira, INC. | $103.72 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $94.28 | 2019 | |
| Kyowa Kirin, INC. | $74.47 | 2022 | |
| Botanix Sb INC | $44.25 | 2025 | Sofdra |
| Merz North America, INC. | $30.36 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $16.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Poche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.